Chi Mei Hospital was approved for allogenic dendritic cell therapy on “Stage I to III solid cancers that have ineffective conventional treatment" by Taiwan FDA on August 6, 2020.

Chi Mei Hospital was approved for allogenic dendritic cell therapy on “Stage I to III solid cancers that have ineffective conventional treatment" by Taiwan FDA on August 6, 2020.

"Chi Mei Hospital" is one of the Changsheng International Biotechnology Cooperative Medical Institutes. It was approved by the Ministry of Health and Welfare on August 6, 2020. The Ministry of Health and Welfare approved the "Stage 1 to 3 solid cancer that has failed standard treatment". Somatic immune dendritic cell (Dendritic cell, referred to as DC) therapy, provides relevant treatment courses for patients who meet the conditions for admission, and its indications are: multitype glioblastoma and secondary brain cancer, epithelial ovarian cancer, pancreatic cancer Visceral cancer, prostate cancer, head and neck cancer, liver cancer, breast cancer, colorectal cancer, etc.

BACK